SAN CARLOS, Calif.--(BUSINESS WIRE)--Cellerant Therapeutics today announced the presentation of positive preclinical data using highly purified hematopoietic (blood forming) stem cells (HSC) in a mouse study of lupus at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH) in Orlando, Florida.
